Malignant mesothelioma - The UK experience

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  O'Brien, Mary E R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Active symptom control; MVP (mitomycin, vinblastine and cisplatin); Natural history of mesothelioma; SRL172; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; MITOMYCIN; NAVELBINE; SRL 172; UNCLASSIFIED DRUG; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INFECTION; MALIGNANT MESOTHELIOMA; NAUSEA; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; GREAT BRITAIN; HUMANS; MESOTHELIOMA; MITOMYCINS; VINBLASTINE;

EID: 3142686656     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.024     Document Type: Conference Paper

References (8)

1. Peto J., Hodgson J.T., Matthews F.E., Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet. 345:1995;535-539
2. Edwards J.G., Abrams K.R., Leverment J.N., Spyt T.J., Waller D.A., O'Byrne K.J. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 55:2000;731-735
3. Middleton G.W., Smith I.E., O'Brien M.E., Norton A., Hickish T., Priest K., et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann. Oncol. 9:1998;269-273
4. Steele J.P.C., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 18:2000;3912-3917
5. Grange J.M., Stanford J.L., Rook G.A.W. Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet. 345:1995;1350-1352
6. O'Brien M.E., Saini A., Smith I.E., Webb A., Gregory K., Mendes R., et al. A pilot randomised study of SRL172 combined with chemotherapy in patients with advanced inoperable non-small cell lung cancer and mesothelioma. Br. J. Cancer. 83:2000;853-857
7. Assersohn L., Souberbielle B.E., O'Brien M.E., Archer C.D., Mendes R., Bass R., et al. A randomised pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Br. J. Cancer. 83(Suppl 1):2000;43
8. Mendes R., O'Brien M.E., Mitra A., Norton A., Gregory R.K., Padhani A.R., et al. Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br. J. Cancer. 86(3):2002;336-341